Adma Biologics, Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was ASCENIV at $124.7 million, 88% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
519
|
141
|
124
|
114
|
139
|
134
|
122
|
115
|
118
|
| ASCENIV |
433
share 83.3%
|
125
+30.7%
share 88.4%
|
103
+23.5%
share 82.7%
|
97
+27.7%
share 85.1%
|
107
share 77.2%
|
95
share 71.1%
|
83
share 68.3%
|
76
share 66.5%
|
—
|
| BIVIGAM |
77
share 14.9%
|
15
-35.2%
share 10.9%
|
19
-48.5%
share 15.6%
|
15
-54.0%
share 13.5%
|
27
share 19.4%
|
24
share 17.7%
|
38
share 30.9%
|
34
share 29.2%
|
—
|
| Intermediates And Other |
-8
share -1.6%
|
1
-93.9%
share 0.6%
|
1
+41.4%
share 1.0%
|
1
-78.5%
share 0.7%
|
-11
share -8.1%
|
15
share 11.2%
|
1
share 0.8%
|
4
share 3.4%
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ramsey, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1368514
- Former names
- R&R ACQUISITION VI, INC (until Feb 21, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.